{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:16:46Z","timestamp":1788401806407,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T00:00:00Z","timestamp":1500336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T00:00:00Z","timestamp":1500336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine were evaluated in HIV-positive Spanish MSM. The prevalence of High Squamous Intraepithelial Lesions (HSIL) and genotypes of high-risk human papillomavirus (HR-HPV) were also determined, as well as risk factors associated with the presence of HR-HPV in anal mucosa.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a randomised, double blind, placebo-controlled trial of the quadrivalent HPV (qHPV) vaccine. The study enrolled from May 2012 to May 2014. Vaccine and placebo were administered at 0, 2 and 6\u00a0months (V1, V2, V3 clinical visits). Vaccine antibody titres were evaluated at 7\u00a0months. Cytology (Thin Prep<jats:sup>\u00ae<\/jats:sup>Pap Test), HPV PCR genotyping (Linear Array HPV Genotyping Test), and high-resolution anoscopy (Zeiss 150 fc\u00a9 colposcope) were performed at V1.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients (n\u00a0=\u00a0162; mean age 37.9\u00a0years) were screened for inclusion; 14.2% had HSIL, 73.1% HR-HPV and 4.5% simultaneous infection with HPV16 and 18. Study participants (n\u00a0=\u00a0129) were randomized to qHPV vaccine or placebo. The most common adverse event was injection-site pain predominating in the placebo group [the first dose (83.6% vs. 56.1%; p\u00a0=\u00a00.0001]; the second dose (87.8% vs. 98.4%; p\u00a0=\u00a00.0001); the third dose (67.7% vs. 91.9%; p\u00a0=\u00a00.0001). The vaccine did not influence either the viral load of HIV or the levels of CD4. Of those vaccinated, 76% had antibodies to HPV vs. 30.2% of those receiving placebo (p\u00a0=\u00a00.0001). In the multivariate analysis, Older age was associated with lower HR-HPV infection (RR 0.97; 95% CI 0.96\u20130.99), and risk factor were viral load of HIV &gt;200 copies\/\u00b5L (RR 1.42 95% CI 1.17\u20131.73) and early commencement of sexual activity (RR 1.35; 95% CI 1.001\u20131.811).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This trial showed significantly higher anti-HR-HPV antibody titres in vaccinated individuals than in unvaccinated controls. There were no serious adverse events attributable to the vaccine. In our cohort, 1 of every 7 patients had HSIL and the prevalence of combined infection by genotypes 16 and 18 was low. This suggests that patients could benefit from receiving qHPV vaccine. Older age was the main protective factor against HR-HPV infection, and non-suppressed HIV viremia was a risk factor.<\/jats:p><jats:p>Clinical trial registration: ISRCTN14732216 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.isrctn.com\/ISRCTN14732216\">http:\/\/www.isrctn.com\/ISRCTN14732216<\/jats:ext-link>).<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12981-017-0160-0","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T12:58:36Z","timestamp":1500382716000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM)"],"prefix":"10.1186","volume":"14","clinical-trial-number":[{"clinical-trial-number":"isrctn14732216","registry":"10.18810\/isrctn"}],"author":[{"given":"Carmen","family":"Hidalgo-Tenorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ram\u00edrez-Taboada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Gil-Anguita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Esquivias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Omar-Mohamed-Balgahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"SamPedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Lopez-Ruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Pasquau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,18]]},"reference":[{"key":"160_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/QAI.0b013e3181b327ca","volume":"52","author":"MS Shiels","year":"2009","unstructured":"Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52:611\u201322.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"160_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1086\/514194","volume":"177","author":"JM Palefsky","year":"1998","unstructured":"Palefsky JM, Holly E, Ralston MR, et al. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis. 1998;177:361\u20137.","journal-title":"J Infect Dis"},{"key":"160_CR3","first-page":"1377","volume":"16","author":"MR Pinzone","year":"2012","unstructured":"Pinzone MR, Fiorica F, Di Rosa M, et al. Non-AIDS-defining cancers among HIV-infected people. Eur Rev Med Pharmacol Sci. 2012;16:1377\u201388.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"160_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/DCR.0000000000000057","volume":"57","author":"IB Fraunhoiz","year":"2014","unstructured":"Fraunhoiz IB, Harberl A, Klauke S, Gute P, Rodel CM. Long-term effects of chemotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of HIV disease. Dis Colon Rectum. 2014;57:423\u201331.","journal-title":"Dis Colon Rectum"},{"key":"160_CR5","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1097\/00002030-199511000-00007","volume":"9","author":"CW Critchlow","year":"1995","unstructured":"Critchlow CW, Surawicz CM, Holmes KK, Kuypers J, Daling JR, Hawes SE, et al. Prospective study of high grade anal squamous intraepithelial neoplasia in a cohort of homosexual men: influence of HIV infection, immunosuppression and human papillomavirus infection. AIDS. 1995;9:1255\u201362.","journal-title":"AIDS"},{"key":"160_CR6","doi-asserted-by":"publisher","first-page":"e92376","DOI":"10.1371\/journal.pone.0092376","volume":"27","author":"C Hidalgo-Tenorio","year":"2014","unstructured":"Hidalgo-Tenorio C, Rivero-Rodriguez M, Gil-Anguita C, et al. Antiretroviral therapy as a factor protective against anal dysplasia in HIV-infected males who have sex with males. PLoS ONE. 2014;27:e92376. doi:10.1371\/journal.pone.0092376.","journal-title":"PLoS ONE"},{"key":"160_CR7","first-page":"206","volume":"6","author":"SA Salati","year":"2012","unstructured":"Salati SA, Al Kadi A. Anal cancer\u2014a review. Int J Heal Sci. 2012;6:206\u201330.","journal-title":"Int J Heal Sci"},{"key":"160_CR8","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1093\/infdis\/jir637","volume":"204","author":"AG Nyitray","year":"2011","unstructured":"Nyitray AG, Carvalho da Silva RJ, Baggio ML, et al. Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: the HPV in Men Study. J Infect Dis. 2011;204:1711\u201322.","journal-title":"J Infect Dis"},{"key":"160_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.7326\/0003-4819-138-6-200303180-00008","volume":"183","author":"C Piketty","year":"2003","unstructured":"Piketty C, Darragh TM, Da Costa M, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med. 2003;183:453\u20139.","journal-title":"Ann Intern Med"},{"key":"160_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.medcli.2012.05.044","volume":"140","author":"C Hidalgo-Tenorio","year":"2013","unstructured":"Hidalgo-Tenorio C, Rivero Rodr\u00edguez M, Concha A, et al. CD4 lymphocytes as a protective factor against infection by oncogenic genotypes of human papillomavirus in the anal mucosa of men who have sex with human immunodeficiency virus positive men. Med Clin (Barc). 2013;140:193\u20139.","journal-title":"Med Clin (Barc)"},{"key":"160_CR11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.7326\/0003-4819-149-5-200809020-00004","volume":"149","author":"PV Chin-Hong","year":"2008","unstructured":"Chin-Hong PV, Berry JM, Cheng SC, et al. Comparison of patient- and clinician-collected anal cytology samples to screen for human papillomavirus-associated anal intraepithelial neoplasia in men who have sex with men. Ann Intern Med. 2008;149:300\u20136.","journal-title":"Ann Intern Med"},{"key":"160_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/QAD.0b013e328333ab8e","volume":"24","author":"M Nathan","year":"2010","unstructured":"Nathan M, Singh N. Performance of anal cytology in a clinical setting when measured against histology and high-resolution anoscopy findings. AIDS. 2010;24:373\u20139.","journal-title":"AIDS"},{"key":"160_CR13","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/QAD.0b013e328339e592","volume":"24","author":"IE Salit","year":"2011","unstructured":"Salit IE, Lytwyn A, Raboud J, et al. The role of cytology (Pap test) and human papillomavirus testing in anal cancer screening. AIDS. 2011;24:1307\u201313.","journal-title":"AIDS"},{"key":"160_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/dc.20212","volume":"33","author":"AE Walts","year":"2005","unstructured":"Walts AE, Thomas P, Bose S. Anal cytology: is there a role for reflex HPV DNA testing? Diagn Cytopathol. 2005;33:152\u20136.","journal-title":"Diagn Cytopathol"},{"key":"160_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/DCR.0b013e31819736aa","volume":"52","author":"SE Goldstone","year":"2009","unstructured":"Goldstone SE, Enyinna ChS, Davis TW. Detection of oncogenic human papillomavirus and other predictors of anal high-grade dysplasia in men who have sex with men with abnormal cytology. Dis Colon Rectum. 2009;52:31\u20139.","journal-title":"Dis Colon Rectum"},{"key":"160_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/DCR.0b013e31819793d9","volume":"52","author":"JM Berry","year":"2009","unstructured":"Berry JM, Palefsky JM, Jay N, Cheng SC, Darragh TM, Chin-Hong PV. Performance characteristics of anal cytology and human paillomavirus testing in patients with high resolution anoscopy-guided biopsy of high grade anal intraepithelial neoplasia. Dis Colon Rectum. 2009;52:239\u201347.","journal-title":"Dis Colon Rectum"},{"key":"160_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2014.03.008","author":"L Padilla-Espa\u00f1a","year":"2014","unstructured":"Padilla-Espa\u00f1a L, Repiso-Jim\u00e9nez B, Fern\u00e1ndez-S\u00e1nchez F, et al. Usefulness of human papillomavirus testing in anal intraepithelial neoplasia screening in a risk behaviour population. Enferm Infecc Microbiol Clin. 2014. doi:10.1016\/j.eimc.2014.03.008.","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"160_CR18","doi-asserted-by":"publisher","first-page":"e0123590","DOI":"10.1371\/journal.pone.0123590","volume":"10","author":"C Hidalgo-Tenorio","year":"2015","unstructured":"Hidalgo-Tenorio C, Rivero-Rodriguez M, Gil-Anguita C, et al. The role of polymerase chain reaction of high-risk human papilloma virus in the screening of high-grade squamous intraepithelial lesions in the anal mucosa of human immunodeficiency virus-positive males having sex with males. PLoS ONE. 2015;10:e0123590. doi:10.1371\/journal.pone.0123590.","journal-title":"PLoS ONE"},{"key":"160_CR19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/QAD.0b013e3283434594","volume":"25","author":"JM Lam","year":"2011","unstructured":"Lam JM, Hoch JS, Tinmouth J, Sano M, Raboud J, Salit IE. Cost-effectiveness of screening for anal precancers in HIV-positive men. AIDS. 2011;25:635\u201342.","journal-title":"AIDS"},{"key":"160_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/0969141314522454","volume":"21","author":"JU Lam","year":"2014","unstructured":"Lam JU, Rebolj M, Dugu\u00e9 PA, Bonde J, von Euler-Chelpin M, Lynge E. Condom use in prevention of human papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies. J Med Screen. 2014;21:38\u201350. doi:10.1177\/0969141314522454.","journal-title":"J Med Screen"},{"issue":"12P2","key":"160_CR21","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1016\/j.lpm.2014.10.001","volume":"43","author":"S de Sanjos\u00e9","year":"2014","unstructured":"de Sanjos\u00e9 S, Bruni L, Alemany L. HPV in genital cancers (at the exception of cervical cancer) and anal cancers. La Presse Med. 2014;43(12P2):e423\u20138. doi:10.1016\/j.lpm.2014.10.001.","journal-title":"La Presse Med"},{"key":"160_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1056\/NEJMoa0909537","volume":"364","author":"AR Giuliano","year":"2011","unstructured":"Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364:401\u201311.","journal-title":"N Engl J Med"},{"key":"160_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1128\/CVI.05208-11","volume":"19","author":"RJ Hillman","year":"2012","unstructured":"Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Vardas E, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6\/11\/16\/18) vaccine in males 16 to 26\u00a0years old. Clin Vaccine Immunol. 2012;19:261\u20137.","journal-title":"Clin Vaccine Immunol"},{"key":"160_CR24","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","volume":"365","author":"JM Palefsky","year":"2011","unstructured":"Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365:1576\u201385.","journal-title":"N Engl J Med"},{"key":"160_CR25","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1086\/656320","volume":"202","author":"T Wilkin","year":"2010","unstructured":"Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010;202:1246\u201353.","journal-title":"J Infect Dis"},{"key":"160_CR26","unstructured":"Wilkin T, Chen H, Cespedes M, Paczuski P, Godefrey C, Luque A, et al. ACTG A5298: a phase 3 trial of the quadrivalent HPV vaccine in older HIV\u00a0+\u00a0Adults. CROI, febrero 22\u201325. Boston. USA; 2016."},{"key":"160_CR27","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa021641","volume":"348","author":"N Mu\u00f1oz","year":"2003","unstructured":"Mu\u00f1oz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518\u201327.","journal-title":"N Engl J Med"},{"key":"160_CR28","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1001\/jama.287.16.2114","volume":"287","author":"D Solomon","year":"2002","unstructured":"Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114\u20139.","journal-title":"JAMA"},{"key":"160_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/LGT.0b013e31825c31dd","volume":"16","author":"TM Darragh","year":"2012","unstructured":"Darragh TM, Colgan TJ, Cox JT, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis. 2012;16:205\u201342.","journal-title":"J Low Genit Tract Dis"},{"key":"160_CR30","doi-asserted-by":"publisher","first-page":"e92376","DOI":"10.1371\/journal.pone.0092376","volume":"27","author":"C Hidalgo-Tenorio","year":"2014","unstructured":"Hidalgo-Tenorio C, Rivero-Rodriguez M, Gil-Anguita C, et al. Antiretroviral therapy as a factor protective against anal dysplasia in HIV-infected males who have sex with males. PLoS ONE. 2014;27:e92376.","journal-title":"PLoS ONE"},{"key":"160_CR31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Series B (methodological). J R Stat Soc. 1995;57:289\u2013300.","journal-title":"J R Stat Soc"},{"key":"160_CR32","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/infdis\/jit657","volume":"209","author":"L Toft","year":"2014","unstructured":"Toft L, Storgaard M, M\u00fcller M, Sehr P, Bonde J, Tolstrup M, et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis. 2014;209:1165\u201373.","journal-title":"J Infect Dis"},{"key":"160_CR33","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1016\/j.vaccine.2015.08.072","volume":"33","author":"AR Giuliano","year":"2015","unstructured":"Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA, et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27\u201345\u00a0years)\u2014the MAM Study. Vaccine. 2015;33:5640\u20136.","journal-title":"Vaccine"},{"key":"160_CR34","doi-asserted-by":"publisher","first-page":"6892","DOI":"10.1016\/j.vaccine.2015.06.088","volume":"33","author":"X Castellsagu\u00e9","year":"2015","unstructured":"Castellsagu\u00e9 X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33:6892\u2013901.","journal-title":"Vaccine."},{"key":"160_CR35","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/DCR.0000000000000095","volume":"57","author":"E Sendagorta","year":"2014","unstructured":"Sendagorta E, Herranz P, Guadalajara H, et al. Prevalence of abnormal anal cytology and high grade squamous intraepithelial lesions among a cohort of HIV-infected men who have sex with men. Dis Colon Rectum. 2014;57:475\u201381.","journal-title":"Dis Colon Rectum"},{"key":"160_CR36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/infdis\/jiq016","volume":"203","author":"S Goldstone","year":"2011","unstructured":"Goldstone S, Palefsky JM, Giuliano AR, et al. Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J Infect Dis. 2011;203:66\u201374.","journal-title":"J Infect Dis"},{"key":"160_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/QCO.0b013e3283229fc8","volume":"22","author":"A Kreuter","year":"2009","unstructured":"Kreuter A, Wieland U. Human papillomavirus-associated diseases in HIV-infected men who have sex with men. Curr Opin Infect Dis. 2009;22:109\u201314.","journal-title":"Curr Opin Infect Dis"},{"key":"160_CR38","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4149\/neo_2015_037","volume":"62","author":"J Slama","year":"2015","unstructured":"Slama J, Sehnal B, Dusek L, Zima T, Cibula D. Impact of risk factors on prevalence of anal HPV infection in women with simultaneous cervical lesion. Neoplasma. 2015;62:308\u201314.","journal-title":"Neoplasma"},{"key":"160_CR39","doi-asserted-by":"publisher","first-page":"e0125120","DOI":"10.1371\/journal.pone.0125120","volume":"10","author":"Z Li","year":"2015","unstructured":"Li Z, Zhang H, Li X, et al. Anal human papillomavirus genotyping among HIV-positive men who have sex with men in Xi\u2019an, China. PloS ONE. 2015;10:e0125120. doi:10.1371\/journal.pone.0125120.","journal-title":"PloS ONE"},{"key":"160_CR40","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/OLQ.0000000000000244","volume":"42","author":"CJ Alberts","year":"2015","unstructured":"Alberts CJ, van Rooijen MS, Prins M, Pawlita M, van der Loeff MFS, Waterboer T. HIV is an important risk factor for human papillomavirus types 16 and 18 seropositivity among sexually active men who have sex with men. Sex Transm Dis. 2015;42:129\u201334.","journal-title":"Sex Transm Dis"},{"key":"160_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/OLQ.0b013e31825aa764","volume":"39","author":"EM van der Snoek","year":"2012","unstructured":"van der Snoek EM, van der Ende ME, den Hollander JC, Schutten M, Neumann HA, van Doornum GJ. Use of highly active antiretroviral therapy is associated with lower prevalence of anal intraepithelial neoplastic lesions and lower prevalence of human papillomavirus in HIV-infected men who have sex with men. Sex Transm Dis. 2012;39:495\u2013500. doi:10.1097\/OLQ.0b013e31825aa764.","journal-title":"Sex Transm Dis"},{"key":"160_CR42","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1097\/01.aids.0000181012.62385.4a","volume":"19","author":"JM Palefsky","year":"2005","unstructured":"Palefsky JM, Holly EA, Efirdc JT, et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS. 2005;19:1407\u201314.","journal-title":"AIDS"},{"key":"160_CR43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/QAD.0000000000000874","volume":"30","author":"RB Geskus","year":"2016","unstructured":"Geskus RB, Gonz\u00e1lez C, Torres M, Del Romero J, Viciana P, Masi\u00e1 M, et al. Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men: estimates and risk factors. AIDS. 2016;30:37\u201344.","journal-title":"AIDS."},{"key":"160_CR44","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1471-2334-11-150","volume":"11","author":"SG Parisi","year":"2011","unstructured":"Parisi SG, Cruciani M, Scaggiante R, et al. Anal and oral human papillomavirus (HPV) infection in HIV infected subjects in Northern Italy: a longitudinal cohort study among men who have sex with men. BMC Infect Dis. 2011;11:150.","journal-title":"BMC Infect Dis"},{"key":"160_CR45","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/infdis\/jiu139","volume":"210","author":"X Castellsagu\u00e9","year":"2014","unstructured":"Castellsagu\u00e9 X, Naud P, Chow SN, Wheeler CM, Germar MJ, Lehtinen M, et al. Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16\/18 antibodies: analysis of the control arm of PATRICIA. J Infect Dis. 2014;210:517\u201334.","journal-title":"J Infect Dis"},{"key":"160_CR46","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1093\/infdis\/jiv753","volume":"213","author":"DC Beachler","year":"2016","unstructured":"Beachler DC, Jenkins G, Safaeian M, Kreimer AR, Wentzensen N. Natural acquired immunity against subsequent genital human papillomavirus infection: a systematic review and meta-analysis. J Infect Dis. 2016;213:1444\u201354.","journal-title":"J Infect Dis"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-017-0160-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-017-0160-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-017-0160-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T15:53:14Z","timestamp":1719330794000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-017-0160-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,18]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["160"],"URL":"https:\/\/doi.org\/10.1186\/s12981-017-0160-0","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,18]]},"assertion":[{"value":"2 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"34"}}